Medical Science
| Open Access |
DOI: CD95 (Fas Receptor) As A Biomarker Of Β-Cell Apoptosis In Children With Type 1 Diabetes Mellitus Following COVID-19 Infection
Malika D. Aripova , Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turaqulov, Tashkent, Uzbekistan Feruza A. Khaydarova , Republican Specialized Scientific and Practical Medical Center of Endocrinology named after Academician E.Kh. Turaqulov, Tashkent, UzbekistanAbstract
Background: The COVID-19 pandemic has been associated with increased incidence and severity of type 1 diabetes mellitus (T1DM) in children, but pathogenic mechanisms remain unclear.
Objective: To investigate CD95 (Fas receptor) as a biomarker of β-cell apoptosis in children with T1DM following COVID-19 and assess its prognostic value.
Methods: Prospective cohort study of 100 children (6-17 years) with newly diagnosed T1DM: 50 with confirmed prior SARS-CoV-2 infection and 50 controls. Serum CD95, autoantibodies (anti-GAD, anti-IAA, anti-ICA), inflammatory markers (IL-6), and endothelial dysfunction markers (ICAM-1, VCAM-1) were measured at diagnosis, 6, and 24 months.
Results: Post-COVID-19 patients showed markedly elevated CD95 (249.5±72.3 vs. 4.87 pg/mL in controls, p<0.001), representing >50-fold increase. CD95 correlated significantly with autoantibody titers (r=0.58, p<0.001), IL-6 (r=0.67, p<0.001), and disease severity. The post-COVID-19 group had higher diabetic ketoacidosis frequency (38% vs. 16%, p<0.05), greater metabolic decompensation (HbA1c 10.6±2.5% vs. 9.12±0.46%, p<0.05), and no remission phase. A combined risk score incorporating CD95 >100 pg/mL, IL-6 >5 pg/mL, VCAM-1 >150 ng/mL, and ≥2 autoantibodies predicted severe disease (sensitivity 92.1%, specificity 90.0%, AUC 0.94).
Conclusions: CD95 is a valuable biomarker of accelerated β-cell apoptosis in post-COVID-19 T1DM, enabling risk stratification and personalized management.
Keywords
Type 1 diabetes mellitus, COVID-19, CD95
References
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69-82.
Barrett CE, et al. Risk for Newly Diagnosed Diabetes After SARS-CoV-2 Infection. MMWR. 2022;71:59-65.
Kamrath C, et al. Ketoacidosis in Children With Newly Diagnosed Type 1 Diabetes During COVID-19. JAMA. 2020;324:801-804.
Unsworth R, et al. New-Onset Type 1 Diabetes in Children During COVID-19. Diabetes Care. 2020;43:e170-e171.
Rubino F, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020;383:789-790.
Khunti K, et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021;44:2645-2655.
Yang L, et al. SARS-CoV-2 Tropism in Human Cells and Organoids. Cell Stem Cell. 2020;27:125-136.
Müller JA, et al. SARS-CoV-2 infects pancreatic β-cells. Nat Metab. 2021;3:149-165.
Copaescu A, et al. IL-6 in cytokine storm with SARS-CoV-2. J Allergy Clin Immunol. 2020;146:518-534.
Mobasheri L, et al. SARS-CoV-2 triggering autoimmune diseases. Cytokine. 2022;154:155873.
Peter ME, Krammer PH. CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol. 1998;10:545-551.
Liadis N, et al. Caspase-3 β-cell apoptosis in autoimmune diabetes. Mol Cell Biol. 2005;25:3620-3629.
Cnop M, et al. β-cell death in diabetes. Diabetes. 2005;54:S97-S107.
Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365.
Mahran YF. Lymphocyte apoptosis in type 1 diabetes. Egypt J Pediatr Allergy Immunol. 2008;6:57-67.
Bradshaw EM, et al. Monocytes secrete proinflammatory cytokines in type 1 diabetes. J Immunol. 2009;183:4432-4439.
Scheller J, et al. Interleukin-6 properties. Biochim Biophys Acta. 2011;1813:878-888.
Eizirik DL, et al. Inflammation in insulitis and β-cell loss. Nat Rev Endocrinol. 2009;5:219-226.
Rewers M, et al. SARS-CoV-2 and Presymptomatic Type 1 Diabetes. JAMA. 2022;328:1252-1255.
Friedl N, et al. Progression to Type 1 Diabetes After COVID-19. JAMA. 2024;332:501-502.
Download and View Statistics
Copyright License
Copyright (c) 2026 Malika D. Aripova, Feruza A. Khaydarova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.